Evidence map›Paper›PMID 33892050›Full record

ArticleNeurobiology of disease2021

Genetic diversity of axon degenerative mechanisms in models of Parkinson's disease.

Owen M Peters, Alexandra Weiss, Jake Metterville, Lina Song, Robert Logan, Gaynor A Smith, Michael A Schwarzschild, Christian Mueller, Robert H Brown, Marc Freeman

Open access · goldAbstract read
In one paragraph

Article in Neurobiology of disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.2field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Inflammatory cytokine upd3 induces axon length-dependent synapse removal by glia.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. NADCell insight · 2022
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Owen M PetersDepartment of Neurobiology, University of Massachusetts Medical School, Worcester, MA 01655, USA; Department of Neurology, University of Massachusetts Medical School, Worcester, MA 01655, USA. Electronic address: petersom@cardiff.ac.uk.
Alexandra WeissDepartment of Neurology, University of Massachusetts Medical School, Worcester, MA 01655, USA.
Jake MettervilleDepartment of Neurology, University of Massachusetts Medical School, Worcester, MA 01655, USA.
Lina SongHorae Gene Therapy Center, University of Massachusetts Medical School, Worcester, MA 01655, USA.
Robert LoganMolecular Neurobiology Laboratory, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA; Eastern Nazarene College, Quincy, MA 02170, USA.
Gaynor A SmithDepartment of Neurobiology, University of Massachusetts Medical School, Worcester, MA 01655, USA.
Michael A SchwarzschildMolecular Neurobiology Laboratory, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA.
Christian MuellerHorae Gene Therapy Center, University of Massachusetts Medical School, Worcester, MA 01655, USA.
Robert H BrownDepartment of Neurology, University of Massachusetts Medical School, Worcester, MA 01655, USA.
Marc FreemanDepartment of Neurobiology, University of Massachusetts Medical School, Worcester, MA 01655, USA.
University of Massachusetts Chan Medical School · USHarvard University · USMassachusetts General Hospital · US

Funding

Molecular Mechanisms of Axon DegenerationR01NS059991 · NINDS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI FREEMAN, MARC R · 2008 to 2023
$5.4M
Next-generation antisense therapeutics for ALS and frontotemporal dementiaR01NS111990 · NINDS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI Robert H Brown, Jonathan K Watts · 2019 to 2026
$5.2M
Urate-LRRK2 interactions in Parkinson's diseaseR01NS110879 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI SCHWARZSCHILD, MICHAEL A · 2019 to 2023
$2.0M
Medical Research Council MC_PC_16030/1NINDS NIH HHS R01 NS059991NINDS NIH HHS R01 NS110879NINDS NIH HHS R01 NS111990
6 · The paper itself

Abstract

Parkinson's disease (PD) is the most common form of neurodegenerative movement disorder, associated with profound loss of dopaminergic neurons from the basal ganglia. Though loss of dopaminergic neuron cell bodies from the substantia nigra pars compacta is a well-studied feature, atrophy and loss of their axons within the nigrostriatal tract is also emerging as an early event in disease progression. Genes that drive the Wallerian degeneration, like Sterile alpha and toll/interleukin-1 receptor motif containing (Sarm1), are excellent candidates for driving this axon degeneration, given similarities in the morphology of axon degeneration after axotomy and in PD. In the present study we assessed whether Sarm1 contributes to loss of dopaminergic projections in mouse models of PD. In Sarm1 deficient mice, we observed a significant delay in the degeneration of severed dopaminergic axons distal to a 6-OHDA lesion of the medial forebrain bundle (MFB) in the nigrostriatal tract, and an accompanying rescue of morphological, biochemical and behavioural phenotypes. However, we observed no difference compared to controls when striatal terminals were lesioned with 6-OHDA to induce a dying back form of neurodegeneration. Likewise, when PD phenotypes were induced using AAV-induced alpha-synuclein overexpression, we observed similar modest loss of dopaminergic terminals in Sarm1 knockouts and controls. Our data argues that axon degeneration after MFB lesion is Sarm1-dependent, but that other models for PD do not require Sarm1, or that Sarm1 acts with other redundant genetic pathways. This work adds to a growing body of evidence indicating Sarm1 contributes to some, but not all types of neurodegeneration, and supports the notion that while axon degeneration in many context appears morphologically similar, a diversity of axon degeneration programs exist.

Indexed as

AnimalsArmadillo Domain ProteinsAxonsCytoskeletal ProteinsGenetic VariationMaleMiceMice, Inbred C57BLMice, KnockoutMice, TransgenicNerve DegenerationOxidopamineParkinsonian DisordersArmadillo Domain ProteinsCytoskeletal ProteinsOxidopamineSARM1 protein, mouseAlpha-synucleinAxon destructionAxotomyParkinson's diseaseSarm1

Identifiers

PMID33892050
PMCPMC8292971
OpenAlexW3152994345

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.